Announcing Our Femtech Panelists for #LATechWeek @ Neuehouse Venice!

#LATechWeek is off to the races and our event is SOLD OUT! We are excited to announce our incredible Femtech Salon line up for our Hollywood, Health, and Gender Equity Experiential Lounge with our cohosts Fwin Productions and Neuehouse Venice.

🔥 Lauren Wang—CEO + Founder of The Flex Co, the innovation leader for period products @flex.

🔥Emily Collins—Plan A Program Lead of NEXT Life Sciences Inc, a medical device company that plans to deliver a non-hormonal, long lasting, and reversible male contraceptive solution that empowers men and their partners to choose if and when to have a child @planaformen.

🔥 Natalise Kalea Robinson—CEO + Co-founder of Parallel Health, a personalized, precision skin health company. Health innovation leader, Natalise Kalea Robinson, is the Co-Founder + CEO of Parallel Health, a personalized, precision skin health company @yourtrueparallel.

🔥 Val Emanuel—CEO+Co-founder of Rif Care in Los Angeles, CA. As a mother, and activist, she developed a regenerative hemp fiber based period product company with the mission to help people understand the intersection between environmental, mental, sexual and spiritual wellness as one @rifcare.

🔥 Julie Gordon White—CEO + Founder of Bossa Bars Menopause Energy Bars, a delicious plant-based, nutrient-dense, and low-calorie energy bars with all the goodness a menopausal body needs and was named an Oprah Daily Best Menopause Product @bossabarsformenopause.

You will also find Parallel Health and some others giving gua sha facials and microbiome testing in the experiential lounge while enjoying nibbles and drinks before your Friday night out!

Immense thanks to our Femtech Panel sponsor for making this possible:

NEXT Life Sciences is a medical device company that plans to deliver a non-hormonal, long lasting, and reversible male contraceptive solution that empowers men and their partners to choose if and when to have a child. Leveraging a robust IP portfolio and decades of pre-clinical research, the company is now raising a $5M financing round for their in-human trials before commercialization.